Omega-3-acid ethyl esters (Lovaza)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Severe Hypertriglyceridemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (23)
Other / comorbidity
NCT03018041 · Joe Chan
2017-09-01 – 2025-03-22 · Kidney Transplantation
What this study did
NCT01633177 · Brigham and Women's Hospital
2011-11 – 2024-05-30 · Type 2 Diabetes
What this study did
NCT01813006 · Nordlandssykehuset HF
2013-03 – 2017-12 · Familial Hypercholesterolemia
What this study did
NCT02625870 · Jiangsu HengRui Medicine Co., Ltd.
2015-12 – 2016-12 · Hypertriglyceridemia
What this study did
NCT01686568 · Mayo Clinic
2012-12-21 – 2015-06-08 · Insulin Resistance
What this study did
NCT02035215 · Kuhnil Pharmaceutical Co., Ltd.
2014-01 – 2014-12 · Hyperlipidemia, Familial Combined
What this study did
NCT00729430 · Brigham and Women's Hospital
2008-08 – 2014-07 · Myocardial Infarction, Death, Sudden, Cardiac
What this study did
NCT00944229 · Columbia University
2010-01 – 2014-03 · Heart Failure
What this study did
NCT01367145 · Medical University of Vienna
2011-01 – 2014-03 · Peripheral Arterial Disease
What this study did
NCT01725646 · Excelsior
2011-07 – 2013-08 · Hypertriglyceridemia
What this study did
NCT00549692 · Kuhnil Pharmaceutical Co., Ltd.
2007-11 – 2012-09 · IgA Nephropathy
What this study did
NCT01277237 · University of Edinburgh
2010-09 – 2012-08 · Non Alcoholic Fatty Liver Disease
What this study did
NCT00935766 · Denver Health and Hospital Authority
2009-09 – 2012-03 · Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases, Diabetes, Cardiovascular Disease, Glucose Metabolism Disorders, Hypertension
What this study did
NCT00069784 · Sanofi
2003-08 – 2011-12 · Diabetes Mellitus, Non-Insulin-Dependent
What this study did
NCT01092390 · Johns Hopkins University
2010-03 – 2011-05 · Diabetes
What this study did
NCT01350999 · Takeda
2009-11 – 2011-01 · Hypertriglyceridemia
What this study did
NCT01350973 · Takeda
2009-11 – 2010-12 · Hypertriglyceridemia
What this study did
NCT00402363 · GlaxoSmithKline
2006-11 – 2010-01 · Fibrillation, Atrial
What this study did
NCT00435045 · GlaxoSmithKline
2007-02 – 2007-10 · Hypertriglyceridemia
What this study did
NCT00246701 · GlaxoSmithKline
2005-11-01 – 2006-06-01 · Hypertriglyceridemia
What this study did
NCT00294216 · Pronova BioPharma
2003-08 – 2005-07 · Cardiovascular Disease
What this study did
NCT01422317 · Helse Stavanger HF
1995-09 – 2002-12 · Coronary Disease, Myocardial Infarction
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT05281562 · Prisma Health-Midlands
2023-02-08 – 2023-03-20 · Diabetes Mellitus, Diabetic Peripheral Neuropathy, Diabetic Foot Ulcer
What this study did
NCT00915902 · Babu Balagopal
2009-07 – 2012-09 · Hypertriglyceridemia
What this study did
NCT00149409 · Medical University of Vienna
2005-09 – 2008-02 · Chronic Heart Failure
What this study did
Phase 2 (21)
Severe Hypertriglyceridemia
NCT01208961 · AstraZeneca
2010-09 – 2010-11 · Severe Hypertriglyceridemia
What this study did
Other / comorbidity
NCT06195306 · National Cancer Institute (NCI)
2025-07-28 – 2028-01-01 · Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
What this study did
NCT03598309 · H. Lee Moffitt Cancer Center and Research Institute
2019-06-05 – 2026-05 · Lung Diseases, Lung Cancer, Protection Against
What this study did
NCT06434948 · University of Missouri-Columbia
2026-03-03 – 2026-04-29 · Postoperative Delirium
What this study did
NCT03831698 · University of Kansas Medical Center
2019-02-06 – 2024-08 · Colorectal Cancer, Lynch Syndrome
What this study did
NCT04268134 · University of Michigan Rogel Cancer Center
2020-07-28 – 2024-02-27 · Breast Cancer
What this study did
NCT02990091 · University of Pennsylvania
2017-01 – 2023-12 · TBI
What this study did
NCT02899741 · Seoul National University Hospital
2016-08 – 2018-11 · Epilepsy
What this study did
NCT01252290 · Carol Fabian, MD
2010-11 – 2013-05 · Breast Cancer
What this study did
NCT01252277 · Carol Fabian, MD
2010-11 – 2013-04 · Breast Cancer
What this study did
NCT00517972 · University of Arizona
— · Depression
What this study did
NCT00672633 · Boston Children's Hospital
2008-04 – 2012-03 · Hypertriglyceridemia
What this study did
NCT01202812 · Thomas Jefferson University
2010-10 – 2012-03 · Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
What this study did
NCT01216982 · United States Department of Defense
2010-11 – 2011-06 · Mood Disorders, Depression, Combat Disorders, Stress Disorders
What this study did
NCT00930527 · Columbia University
2009-06 – 2011-05 · Breast Cancer
What this study did
NCT00845845 · University of Illinois at Chicago
2006-03 – 2010-10 · Nonalcoholic Steatohepatitis (NASH), Hepatic Steatosis
What this study did
NCT01001767 · University Hospitals Cleveland Medical Center
2009-04 – 2010-06 · HIV Infections, Heart Disease
What this study did
NCT00805870 · Western Michigan University
2009-03 – 2010-02 · Muscle Damage, Muscle Inflammation
What this study did
NCT00515541 · Invitrox
2007-09 – 2009-06 · Cardiovascular Disease, Bleeding
What this study did
NCT00004448 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1997-11 – 2007-08 · IgA Glomerulonephritis
What this study did
Phase 1/2 (15)
Other / comorbidity
NCT03167164 · ImmunityBio, Inc.
2017-12 – 2021-12-28 · Merkel Cell Carcinoma
What this study did
NCT03169777 · ImmunityBio, Inc.
2018-08 – 2021-12-28 · Colorectal Cancer
What this study did
NCT03169790 · ImmunityBio, Inc.
2017-12 – 2021-12-23 · Non Hodgkin Lymphoma
What this study did
NCT03387098 · ImmunityBio, Inc.
2017-12-28 – 2019-01-15 · Pancreatic Cancer
What this study did
NCT01191177 · Boston Children's Hospital
2011-01 – 2012-01 · Liver Disease, Short Bowel Syndrome
What this study did
NCT01155336 · University of Rochester
2010-06 – 2011-05 · Myocardial Infarction
What this study did
NCT00959842 · Sanford Research
2009-09 – 2010-02 · Hypertriglyceridemia
What this study did
NCT00771914 · University of Rochester
2008-11 – 2009-01 · Increased Drug Resistance
What this study did
Phase 1 (9)
Severe Hypertriglyceridemia
Other / comorbidity
NCT04308889 · Brigham and Women's Hospital
2018-07-02 – 2022-02-22 · Inflammation; Skin, Resolution, Blister
What this study did
NCT03438955 · DongKoo Bio & Pharma
2018-02-01 – 2018-08-31 · Hyperlipidemia, Hypertriglyceridemia
What this study did
NCT01823991 · H. Lee Moffitt Cancer Center and Research Institute
2014-07-30 – 2018-05-02 · Breast Cancer
What this study did
NCT01784042 · Milton S. Hershey Medical Center
2013-03 – 2018-03 · Breast Cancer
What this study did
NCT01282580 · Ohio State University Comprehensive Cancer Center
2010-07 – 2014-08 · Breast Cancer
What this study did
NCT00694746 · Boston University
2008-06 – 2014-03 · Non-alcoholic Fatty Liver Disease, Fatty Liver
What this study did
NCT01526824 · Millard Fillmore Gates Hospital
2011-09 – 2013-09 · Ischemic Stroke, Transient Ischemic Attack
What this study did
NCT00688961 · Sanford Research
2007-06 – 2007-08 · Healthy
What this study did
Phase 4 (31)
Other / comorbidity
NCT00135226 · University of Oxford
2005-03 – 2037-07-31 · Diabetes Mellitus
What this study did
NCT00760513 · University Hospital Southampton NHS Foundation Trust
2009-11-01 – 2018-11-29 · Non-Alcoholic Fatty Liver Disease
What this study did
NCT02839902 · Takeda
2016-12-27 – 2017-08-30 · Hyperlipidemia
What this study did
NCT02010359 · University of Pennsylvania
2014-06 – 2017-07-01 · Obesity
What this study did
NCT01744067 · Oslo University Hospital
2013-11 – 2015-12 · Disorder Related to Renal Transplantation
What this study did
NCT01041521 · Tufts University
2010-01 – 2015-08 · High Triglyceride Level, HIV Infection
What this study did
NCT01301794 · Brigham and Women's Hospital
2012-08 – 2014-08 · Moderate Hypertriglyceridemia.
What this study did
NCT01046604 · East Carolina University
2010-01 – 2013-12 · Mitral Valve Regurgitation, Left Atrium Dilatation and Hypertrophy, Mitochondrial Dysfunction in the Heart, Cardiomyocyte Apoptosis, Cardiac Inflammation
What this study did
NCT00833976 · Massachusetts General Hospital
2009-07 – 2013-03 · High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
What this study did
NCT00934219 · Jewish Hospital, Cincinnati, Ohio
2009-07 – 2012-12 · Hypertriglyceridemia
What this study did
NCT01596842 · Dong-A University
2012-05 – 2012-12 · Hemodialysis Patients, Vitamin D Insufficiency, Vitamin D Deficiency
What this study did
NCT01180764 · University of Utah
2010-08 – 2012-10 · Hypertriglyceridemia
What this study did
NCT00941642 · Huntington Medical Research Institutes
2009-09 – 2012-09 · Non-Alcoholic Fatty Liver Disease
What this study did
NCT00931879 · Eastern Virginia Medical School
2009-10 – 2012-07 · Hypertriglyceridemia, Diabetic Neuropathy
What this study did
NCT00791089 · University of Michigan
2008-11 – 2011-10 · Atrial Fibrillation
What this study did
NCT00437099 · Hospital Universitari Vall d'Hebron Research Institute
2009-02 – 2011-09 · Borderline Personality Disorder.
What this study did
NCT02305355 · Kuhnil Pharmaceutical Co., Ltd.
2009-02 – 2011-02 · Diabetes Mellitus, Type 2, Hypertriglycemia
What this study did
NCT00828178 · Michelle Petri M.D.,MPH
2009-02 – 2011-02 · Systemic Lupus Erythematosus
What this study did
NCT01010399 · Felizarta, Franco, M.D.
2009-09 – 2010-11 · Hypertriglyceridemia, HIV Infection
What this study did
NCT00795717 · Tufts University
2008-07 – 2010-10 · Cardiovascular Disease, HIV Infection
What this study did
NCT00746811 · Provident Clinical Research
2010-01 – 2010-10 · Primary Hypercholesterolemia
What this study did
NCT01778647 · Antonios Likourezos
2009-12 – 2010-07 · Attention Deficit Hyperactivity Disorder
What this study did
NCT00758927 · Inje University
2009-07 – 2010-07 · Diabetes Mellitus, Type 2, Hypercholesterolemia, Hypertriglyceridemia
What this study did
NCT00678743 · Provident Clinical Research
2007-08 – 2009-09 · Dyslipidemias
What this study did
NCT00598910 · Solvay Pharmaceuticals
2007-08 – 2009-03 · Hyper-Triglyceridemia
What this study did
NCT00286234 · University of South Dakota
2007-10 – 2008-12 · Metabolic Syndrome, Hypertriglyceridemia
What this study did
NCT00328536 · Ruhr University of Bochum
2007-04 – 2008-11 · Atherosclerosis, Type 2 Diabetes Mellitus
What this study did
NCT00296153 · Pronova BioPharma
2006-02 – 2007-10 · Human Immunodeficiency Virus, Ischemic Heart Disease
What this study did
NCT00257283 · Pronova BioPharma
2002-11 – 2005-06 · Kidney Failure, Chronic
What this study did
Early phase / not applicable (27)
Other / comorbidity
NCT00682318 · Carsten Skarke, MD
2008-05 – 2029-11 · Healthy
What this study did
NCT01728571 · Brigham and Women's Hospital
2010-07 – 2027-11 · COPD, Asthma, Pulmonary Function, Pneumonia
What this study did
NCT01782352 · Brigham and Women's Hospital
2010-07 – 2024-09 · Age-related Macular Degeneration
What this study did
NCT01821833 · New Mexico Cancer Research Alliance
2016-05-24 – 2022-08-03 · Breast Cancer, Ovarian Neoplasm, Pain
What this study did
NCT01785004 · Brigham and Women's Hospital
2012-07 – 2022-07 · Adiposity
What this study did
NCT01880463 · Brigham and Women's Hospital
2010-07 – 2021-12 · Dry Eye Disease
What this study did
NCT02996240 · The University of Texas Health Science Center at San Antonio
2017-06-12 – 2021-02-22 · Breastcancer
What this study did
NCT01107964 · Milton S. Hershey Medical Center
2010-07 – 2015-06-15 · Dry Eye Syndrome
What this study did
NCT00723398 · Milton S. Hershey Medical Center
2009-03 – 2015-04 · Breast Cancer
What this study did
NCT01813110 · Penn State University
2014-05 – 2015-04 · Inflammatory Responses
What this study did
NCT01624727 · Beth Israel Deaconess Medical Center
2009-06 – 2015-01-15 · Coronary Heart Disease, Metabolic Syndrome
What this study did
NCT00579436 · Philip Kern
2007-01 – 2015-01-15 · Metabolic Syndrome, Insulin Resistance
What this study did
NCT01157780 · University of Tennessee
2008-10 – 2014-12 · Parenteral Nutrition Associated Liver Disease
What this study did
NCT01308957 · Washington University School of Medicine
2011-06 – 2014-12 · Sarcopenia
What this study did
NCT01894581 · University of Colorado, Denver
2014-07 – 2014-12 · Obesity, Fertility
What this study did
NCT00577590 · Washington University School of Medicine
2003-10 – 2012-09 · Diabetes Mellitus, Type II
What this study did
NCT00547716 · University of Missouri, Kansas City
2009-06 – 2012-08 · Hepatitis C
What this study did
NCT01048502 · University of Pennsylvania
2010-01 – 2011-05 · Cardiovascular Disease
What this study did
NCT01002118 · University of Iowa
2008-01-25 – 2011-02-23 · Cardiovascular Disease
What this study did
NCT01034540 · Provident Clinical Research
2010-03 – 2011-02 · Hypertriglyceridemia
What this study did
NCT00794079 · Washington University School of Medicine
2007-06 – 2010-12 · Healthy
What this study did
NCT00743197 · Northwestern University
2008-05 – 2010-05 · Chest Pain
What this study did
NCT00569686 · University of Virginia
2007-09 – 2010-02 · Peripheral Artery Disease
What this study did
NCT00825994 · Massachusetts General Hospital
2008-11 – 2009-06 · Depression
What this study did
NCT00504309 · Penn State University
2007-07 – 2009-01 · Hypertriglyceridemia
What this study did
NCT00454493 · Olive View-UCLA Education & Research Institute
2006-08 – 2008-12 · Coronary Artery Disease
What this study did
NCT00508248 · University of Dundee
2005-01 – 2008-11 · Atrial Fibrillation
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Severe Hypertriglyceridemia
NCT01594983 · Novartis Pharmaceuticals
2012-06 – 2013-07 · Non Familial Chylocmicronemia Syndrome (Non-FCS)
What this study did
Phase 1 (1)
Early phase / not applicable (2)
Other / comorbidity
NCT03443076 · Midwest Center for Metabolic and Cardiovascular Research
2018-02-16 – 2018-04-15 · Bioavailability
What this study did
NCT01712867 · Enzymotec
2012-10 – 2014-12 · Patients With Hypertriglyceridemia
What this study did

Competitive landscape

This drug's own stage for Severe Hypertriglyceridemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Omega-3-Acid Ethyl Esters (Lovaza): this drugApprovedSmall moleculeTriglyceride metabolismnot yet gradedNo reviewed efficacy summary in this indication
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01047683: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect (baseline and 12 weeks): AMR101 (Ethyl Icosapentate) - 2 g/Day -7 Percent change from baseline (IQR -30.1 to 18.6) | AMR101 (Ethyl Icosapentate) - 4 g/Day -26.6 Percent change from baseline (IQR -41.1 to 0) vs Placebo 9.7 Percent change from baseline (IQR -19.2 to 42.3)
Olezarsen (Tryngolza)ApprovedRNA / oligonucleotideAPOC3Reliable signal
NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001)
NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001).
Omega-3-Acid Ethyl Esters A (Omtryg)
ApprovedUS marketing discontinued
Small moleculeTriglyceride synthesis / VLDLnot yet gradedNo reviewed efficacy summary in this indication
DR10624Phase 3Protein / enzyme therapeuticGLP-1R; GCGR; FGF21RPartial signal
NCT06555640: Median triglyceride reduction: 74.5% (12.5 mg), 66.2% (25 mg), 68.9% (50 mg titration) vs 8.0% with placebo
PegozaferminPhase 3Protein / enzyme therapeuticFGFR1c/2c/3c–β-Klotho agonistPartial signalNo reviewed efficacy summary in this indication
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signal
NCT03011450: Percent Change in Fasting TG From Baseline to Week 12 (12 Weeks): K-877 -58.89% (IQR -71.69 to -38.42) vs Placebo -22.94% (IQR -43.98 to 9.67)
NCT03001817: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 (12 Weeks): K-877 -56% (IQR -72.08 to -32.4) vs Placebo -7.97% (IQR -44.78 to 49.87)
Plozasiran (Redemplo)Phase 3RNA / oligonucleotideAPOC3Partial signalNo reviewed efficacy summary in this indication
Volanesorsen (Waylivra)Phase 3RNA / oligonucleotideAPOC3 mRNAPartial signal
NCT02300233: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Volanesorsen Total -71.2% (95% CI -79.3 to -63.2) vs Placebo -0.9% (95% CI -13.9 to 12.2)
HRS-7249Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
ION775Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
SEFA-1024
Phase 2(overall)
Small moleculeHepatic triglyceride/VLDL synthesis pathwayPartial signalNo reviewed efficacy summary in this indication
SolbinsiranPhase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
CS-121Phase 1Gene therapy / editingAPOC3not yet gradedNo reviewed efficacy summary in this indication
CTX310Phase 1Gene therapy / editingANGPTL3not yet gradedNo reviewed efficacy summary in this indication
GC304
Phase 1(overall)
Gene or cell therapy (subtype unspecified)LPL (lipoprotein lipase) genenot yet gradedNo reviewed efficacy summary in this indication
Extended-Release Niacin (Niaspan)DiscontinuedSmall moleculeGPR109A (HCAR2)not yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Omega-3-acid ethyl esters (Lovaza) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 2Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In SituRecruiting
Est. primary completion 2027-01-01 · NCT06195306 · CT.gov ↗
What to watch
2028 (1)
November 2028 (1)
Early phase / not applicableHealthyActive not recruiting
Est. primary completion 2028-11 · NCT00682318 · CT.gov ↗
What to watch

See the full readout calendar ↗